#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Ovarian cancer Dementia Alzheimer's type Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Autologous haematopoietic stem cell transplant Red blood cell abnormality Ectonucleotide pyrophosphatase/phosphodiesterase 1 deficiency Pyogenic sterile arthritis pyoderma gangrenosum and acne syndrome Necrotising enterocolitis neonatal Haemophilia B with anti factor IX Small for dates baby Pneumonia Mitochondrial DNA depletion Acute myeloid leukaemia recurrent Hypersomnia Hypochondroplasia Antisynthetase syndrome Inflammatory myofibroblastic tumour Loeys-Dietz syndrome More trials…

    Learn about Rare Diseases

    Ehlers-Danlos syndrome – Trials in Disease Primary mediastinal large B-cell lymphoma – Treatment Activated PI3 kinase delta syndrome – Basic Information Congenital nephrogenic diabetes insipidus Myxofibrosarcoma – Diagnostics Breast angiosarcoma – Trials in Disease Alexander disease – Basic Information Atypical teratoid/rhabdoid tumour of CNS – Treatment MELAS syndrome – Diagnostics Osteosarcoma – Treatment More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Ocrelizumab Fludarabine Phosphate Relugolix Dexketoprofen Trometamol Dolutegravir Eight Treg Valaciclovir Peginterferon Beta-1A Baloxavir Marboxil Pregabalin Quemliclustat Canakinumab Brivaracetam Tislelizumab Amoxicillin Telmisartan Protrans Blinatumomab GUAIACOL Tx200-Tr101 More therapies…

    Learn about Your Condition

    Testicular germ cell cancer Meniere's disease End stage renal disease Anal fissure BRAF gene mutation Dizziness Cold urticaria Lumbosacral radiculopathy Thymoma Tinnitus Intermittent claudication Dermatitis Cholangitis sclerosing Endometrial cancer stage II Bone hypertrophy More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Angelman’s syndrome

  • A Phase 3 study to evaluate the efficacy and safety of ION582 in children and adults with Angelman syndrome

    Recruiting

    3 1 1
    Investigated Drugs:
    • 2′-O-(2-Methoxyethyl) Modified Antisense Oligonucleotide Targeting Ube3A Antisense Transcript Rna
    Germany Italy Poland Spain

  • A Study Testing the Safety and How Well GTX-102 Works in Adults and Children with Angelman Syndrome

    Recruiting

    2 1 1
    Investigated Drugs:
    • DISODIUM PHOSPHATE
    • APAZUNERSEN
    • Sodium Dihydrogen Phosphate Dihydrate
    France Italy Portugal

  • Study on the Long-Term Safety of GTX-102 for Patients with Angelman Syndrome

    Recruiting

    3 1 1
    Investigated Diseases:
    • Angelman’s syndrome
    Investigated Drugs:
    • Calcium Chloride
    • DISODIUM PHOSPHATE
    • Glucose, Anhydrous
    France Germany Spain

  • Study on the Safety and Effects of ION582 for Patients with Angelman Syndrome

    Recruiting

    2 1 1
    Investigated Diseases:
    • Angelman’s syndrome
    Investigated Drugs:
    • 2′-O-(2-Methoxyethyl) Modified Antisense Oligonucleotide Targeting Ube3A Antisense Transcript Rna
    France Italy

  • Study on the Effects of GTX-102 for Children with Angelman Syndrome

    Not recruiting

    3 1 1
    Investigated Drugs:
    • DISODIUM PHOSPHATE
    • APAZUNERSEN
    • Sodium Dihydrogen Phosphate Dihydrate
    Germany The Netherlands Poland Spain

  • Study on the Safety and Tolerability of Rugonersen in Patients with Angelman Syndrome

    Not recruiting

    1 1 1
    Investigated Diseases:
    • Angelman’s syndrome
    Investigated Drugs:
    • Rugonersen
    Italy The Netherlands Spain

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!